On March 31, Samsung Biologics celebrated Day 1 of its first U.S. manufacturing site in Rockville, Maryland, United States, officially welcoming the Rockville Campus into the company’s global network. Samsung Biologics’ leadership team, including President and CEO John Rim, joined the Rockville team to mark the occasion with a ceremony celebrating the beginning of this next chapter. Among the dignitaries present were Governor of Maryland Wes Moore, South Korean Ambassador to the United States, Kang Kyung-wha, Congresswoman April McClain Delaney, and Montgomery County Executive Marc Elrich, reflecting the importance of the milestone for the local community and the broader biopharma industry.
“During our international trade mission last year, we met with the Samsung Biologics team in Seoul to discuss the economic momentum in Maryland. Today’s ribbon cutting is the realization of that meeting and our state’s momentum,” said Gov. Moore. “South Korea’s largest biotech company is opening its first U.S. manufacturing facility here in Maryland. In the state of Maryland, we are delivering for our people and not playing for second.”
“Samsung Biologics’ investment in Montgomery County is a major win for Maryland and a clear example of how public investment and global partnerships help drive innovation, business and workforce opportunities and improve the health and well-being of our communities,” said Congresswoman April McClain Delaney. “As a member of the House Science, Space, and Technology Committee, I have seen how sustained federal support for research helps attract cutting-edge companies to our region. Located along the I-270 Technology Corridor, this new facility will benefit from Maryland’s uniquely collaborative innovation ecosystem—where federal labs, universities, and industry collaborate to drive progress. We’re proud to welcome Samsung Biologics to our science community and to celebrate their new facility.”
“Samsung Biologics is a global leader in biomanufacturing, known for excellence, scale, and precision, and their decision to establish their first U.S. biomanufacturing presence in Montgomery County, Maryland, speaks volumes about our attractiveness to international companies,” said Montgomery County Executive Marc Elrich. “Montgomery County sits at the heart of the nation’s third-largest biohealth cluster. We are home to the National Institutes of Health, the U.S. Food and Drug Administration, and the University of Maryland’s Institute for Health Computing, alongside a dynamic cluster of private sector companies advancing breakthroughs in biotech, R&D, manufacturing, and health innovation. We are proud to be a County and State designed to move ideas from discovery to delivery. We welcome Samsung Biologics to Montgomery County.”
The expansion represents a meaningful step in further advancing Samsung Biologics’ global manufacturing network with greater flexibility and regional proximity. It supports the company’s geographical diversification strategy, strengthening supply chain resilience and responsiveness to client needs and enabling us to better serve our clients across the U.S. and beyond.
Building on the successful acquisition and integration of the Rockville campus into our global capacity, we are exploring opportunities to further expand our manufacturing footprint in the U.S.
Our Rockville campus has two manufacturing plants with a total capacity of 60 kL in two 20 kL and two 10 kL bioreactors. The facilities enable clinical- to commercial-scale production of drug substance for mammalian cell culture. The integration plan will ensure that Rockville operations adopt Samsung Biologics’ standardized manufacturing framework, ExellenS™, to deliver a reliable, consistent supply of high-quality biomedicines.
With the expertise of over 500 talented employees at the Rockville campus, Samsung Biologics will continue to anticipate and meet growing industry demand while fostering a supportive and inclusive workplace. A thoughtful integration approach will bring together local expertise with Samsung Biologics’ global standards and culture, ensuring strong collaboration across teams. As the company looks ahead to further capacity enhancements, the Rockville campus will play an integral role in advancing agile, reliable biopharmaceutical manufacturing that drives the next generation of life-saving biomedicines.
On March 31, Samsung Biologics celebrated Day 1 of its first U.S. manufacturing site in Rockville, Maryland, United States, officially welcoming the Rockville Campus into the company’s global network. Samsung Biologics’ leadership team, including President and CEO John Rim, joined the Rockville team to mark the occasion with a ceremony celebrating the beginning of this next chapter. Among the dignitaries present were Governor of Maryland Wes Moore, South Korean Ambassador to the United States, Kang Kyung-wha, Congresswoman April McClain Delaney, and Montgomery County Executive Marc Elrich, reflecting the importance of the milestone for the local community and the broader biopharma industry.
“During our international trade mission last year, we met with the Samsung Biologics team in Seoul to discuss the economic momentum in Maryland. Today’s ribbon cutting is the realization of that meeting and our state’s momentum,” said Gov. Moore. “South Korea’s largest biotech company is opening its first U.S. manufacturing facility here in Maryland. In the state of Maryland, we are delivering for our people and not playing for second.”
“Samsung Biologics’ investment in Montgomery County is a major win for Maryland and a clear example of how public investment and global partnerships help drive innovation, business and workforce opportunities and improve the health and well-being of our communities,” said Congresswoman April McClain Delaney. “As a member of the House Science, Space, and Technology Committee, I have seen how sustained federal support for research helps attract cutting-edge companies to our region. Located along the I-270 Technology Corridor, this new facility will benefit from Maryland’s uniquely collaborative innovation ecosystem—where federal labs, universities, and industry collaborate to drive progress. We’re proud to welcome Samsung Biologics to our science community and to celebrate their new facility.”
“Samsung Biologics is a global leader in biomanufacturing, known for excellence, scale, and precision, and their decision to establish their first U.S. biomanufacturing presence in Montgomery County, Maryland, speaks volumes about our attractiveness to international companies,” said Montgomery County Executive Marc Elrich. “Montgomery County sits at the heart of the nation’s third-largest biohealth cluster. We are home to the National Institutes of Health, the U.S. Food and Drug Administration, and the University of Maryland’s Institute for Health Computing, alongside a dynamic cluster of private sector companies advancing breakthroughs in biotech, R&D, manufacturing, and health innovation. We are proud to be a County and State designed to move ideas from discovery to delivery. We welcome Samsung Biologics to Montgomery County.”
The expansion represents a meaningful step in further advancing Samsung Biologics’ global manufacturing network with greater flexibility and regional proximity. It supports the company’s geographical diversification strategy, strengthening supply chain resilience and responsiveness to client needs and enabling us to better serve our clients across the U.S. and beyond.
Building on the successful acquisition and integration of the Rockville campus into our global capacity, we are exploring opportunities to further expand our manufacturing footprint in the U.S.
Our Rockville campus has two manufacturing plants with a total capacity of 60 kL in two 20 kL and two 10 kL bioreactors. The facilities enable clinical- to commercial-scale production of drug substance for mammalian cell culture. The integration plan will ensure that Rockville operations adopt Samsung Biologics’ standardized manufacturing framework, ExellenS™, to deliver a reliable, consistent supply of high-quality biomedicines.
With the expertise of over 500 talented employees at the Rockville campus, Samsung Biologics will continue to anticipate and meet growing industry demand while fostering a supportive and inclusive workplace. A thoughtful integration approach will bring together local expertise with Samsung Biologics’ global standards and culture, ensuring strong collaboration across teams. As the company looks ahead to further capacity enhancements, the Rockville campus will play an integral role in advancing agile, reliable biopharmaceutical manufacturing that drives the next generation of life-saving biomedicines.
Share article
Related Content